Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,305.00DKK
21 Apr 2017
Change (% chg)

-- (--)
Prev Close
kr.1,305.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
308,332
52-wk High
kr.1,489.00
52-wk Low
kr.947.50

Latest Key Developments (Source: Significant Developments)

Genmab Q1 net sales of Darzalex at $255 million
Tuesday, 18 Apr 2017 06:55am EDT 

April 18 (Reuters) - GENMAB A/S GEN.CO:GENMAB ANNOUNCES NET SALES OF DARZALEX®(DARATUMUMAB) FOR FIRST QUARTER OF 2017<<>>.NET SALES OF DARZALEX IN Q1 OF 2017 TOTALED $255 MILLION.SAYS WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC.  Full Article

BRIEF-Genmab A/S says Phase II study in NHL will not proceed
Friday, 31 Mar 2017 02:02am EDT 

Genmab A/S : Phase II study of daratumumab in Non-Hodgkin’S Lymphoma will not proceed to stage 2 of trial . Genmab says Phase II study (CARINA, LYM2001) in NHL will not proceed . Genmab says other ongoing and planned studies with daratumumab in lymphomas and other cancers outside multiple myeloma continue as planned . Genmab says announcement has no impact on other ongoing or planned studies with daratumumab . Collaboration partner for daratumumab, Janssen Biotech, has decided not to initiate stage 2 of Phase II study (CARINA, LYM2001) of daratumumab . Study will not proceed to stage 2 based on results of a data review . Review showed 2 cohorts investigating use of daratumumab monotherapy in relapsed patients with FL, DLBCL didn't reach predefined ORR futility thresholds .In third cohort in study, patients with mantle cell lymphoma (MCL), ORR was not evaluable due to slow recruitment.  Full Article

Genmab A/S says Phase II study in NHL will not proceed
Thursday, 30 Mar 2017 12:29pm EDT 

Genmab A/S : Phase II study of daratumumab in Non-Hodgkin’S Lymphoma will not proceed to stage 2 of trial . Genmab says Phase II study (CARINA, LYM2001) in NHL will not proceed . Genmab says other ongoing and planned studies with daratumumab in lymphomas and other cancers outside multiple myeloma continue as planned . Genmab says announcement has no impact on other ongoing or planned studies with daratumumab . Collaboration partner for daratumumab, Janssen Biotech, has decided not to initiate stage 2 of Phase II study (CARINA, LYM2001) of daratumumab . Study will not proceed to stage 2 based on results of a data review . Review showed 2 cohorts investigating use of daratumumab monotherapy in relapsed patients with FL, DLBCL didn't reach predefined ORR futility thresholds .In third cohort in study, patients with mantle cell lymphoma (MCL), ORR was not evaluable due to slow recruitment.  Full Article

EMA recommends approval of Daiichi Sankyo's anticoagulant
Friday, 24 Feb 2017 07:00am EST 

EU Medicines Agency: EU medicines Agency recommendations for February 2017 . EU Medicines Agency recommends approval Of Daiichi Sankyo's anticoagulant Edoxaban . EU Medicines Agency says adopted positive opinion recommending changes to the terms of the marketing authorisation for the medicinal product Darzalex . EU Medicines Agency recommends approval of Hospira UK Limited's Pemetrexed for treatment of non-small cell lung cancer Source (http://bit.ly/2lCHPks) Further company coverage: [4568.T] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Genmab FY operating income up to DKK 1,053 million
Wednesday, 22 Feb 2017 11:01am EST 

Genmab A/S : Revenue was 1,816 million Danish crowns ($257.45 million) in 2016 compared to 1,133 million crowns in 2015 . Operating income was 1,053 million crowns in 2016 compared to 730 million crowns in 2015 . Sees 2017 revenue of 1,950 million crowns - 2,150 million crowns . Sees 2017 operating income of 900 million - 1,100 million crowns .Projected revenue for 2017 consists primarily of DARZALEX royalties of 930 million – 1,100 million crowns that are based on an estimated $1,100 million – $1,300 million of DARZALEX net sales in 2017 and DARZALEX milestones of 800 million crowns.  Full Article

Genmab raises 2016 financial guidance
Monday, 6 Feb 2017 12:39am EST 

Genmab A/S : Raises its 2016 financial guidance published on Dec. 20, 2016 . Expects FY revenue of 1.79 billion Danish crowns - 1.84 billion Danish crowns ($259.43 million-$266.67 million) against previous guidance of 1.72 billion-1.77 billion crowns . Expects FY operating income of 1.02 billion crowns - 1.07 billion crowns against previous guidance of 895 million-945 million crowns .Says revenue range increased primarily due to higher royalties on net sales of DARZALEX by Janssen and achievement of additional DuoBody milestones.  Full Article

Genmab: net sales of Darzalex in 2016 $572 million
Tuesday, 24 Jan 2017 06:52am EST 

Genmab A/S : Net sales of Darzalex in 2016 totaled $572 million .Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc..  Full Article

Genmab submits Daratumumab to Japan regulators, lifts 2016 income guidance
Tuesday, 20 Dec 2016 01:05am EST 

Danish pharmaceutical company Genmab says: Regulatory application submitted in Japan for daratumumab for relapsed or refractory multiple myeloma . Submission based on data from SIRIUS, CASTOR and POLLUX studies . To receive $10 million in milestone payments from Janssen - financial guidance updated .Now sees 2016 operating income at 895-945 million DKK versus previous guidance of 825-875 million DKK.  Full Article

Genmab announces U.S. FDA approval of Darzalex (Daratumumab) for relapsed multiple myeloma
Monday, 21 Nov 2016 03:46pm EST 

Genmab A/S : Genmab announces U.S. FDA approval of Darzalex (Daratumumab) for relapsed multiple myeloma and updates financial guidance . Genmab will receive milestone payments totaling $65 million from Janssen . Genmab says anticipate that 2016 operating expenses will remain in range of DKK 800 - 850 million . We expect 2016 revenue to be in range of DKK 1,650 million - 1,700 million, an increase of DKK 450 million compared to previous guidance . Genmab says now expect operating income for 2016 to be approximately DKK 825 - 875 million .Expect FY 2016 Darzalex royalties to remain in range of DKK 400 million - 450 million.  Full Article

Genmab says combination of drugs from J&J, Amgen will be tested in study
Thursday, 10 Nov 2016 08:27am EST 

Genmab : Genmab announces phase III study of daratumumab in combination with carfilzomib in multiple myeloma . Genmab - new phase III study combining daratumumab, carfilzomib,dexamethasone in relapsed/refractory multiple myeloma - dosing expected in 2017 . Genmab - first study under clinical trial collaboration and supply agreement between janssen and amgen .Phase iii study of daratumumab is anticipated to start dosing patients in 2017 and will be sponsored by amgen.  Full Article

More From Around the Web

BRIEF-Genmab to present seven abstracts at annual ASCO meeting

* Says seven daratumumab abstracts have been accepted for presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2 – 6